Earnings | Abbott India Ltd (NSE: ABBOTTINDIA): Q4FY23 Results Out; Total Income rises 9% YoY.

Abbott India Ltd is a prominent multinational pharmaceutical company operating in India. Established in 1944, it has emerged as a key player in the Indian pharmaceutical industry. The company distributes its products through independent distributors, primarily within the country. With a strong presence in the market, Abbott India offers a wide range of pharmaceutical products, catering to diverse medical needs. It is known for its commitment to providing high-quality healthcare solutions, leveraging its expertise and innovative research. Abbott India’s contributions to the Indian healthcare sector have established it as a trusted and reliable name in the pharmaceutical industry.

• Abbott India Ltd reported Total Income for Q4 FY23 of ₹1,393 Crore up from ₹1,276 Crore year on year, a growth of 9%.
• Total Expenses for Q4 FY23 of ₹1,084 Crore up from ₹983 Crore year on year, a growth of 10%.
• Consolidated Net Profit of ₹231 Crore, up 9% from ₹211 Crore in the same quarter of the previous year. 
• The Earnings per Share is ₹108.90, up 9% from ₹99.49 in the same quarter of the previous year.